Lan Huang

This inventor holds 23 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Cancer Treatment. Top assignees: Beyondspring Pharmaceuticals, Inc., Beyondspring Inc., Hywe Pharmaceuticals, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lan Huang. Retrieved from https://idiyas.com/inventor/lan-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 14)

% Patents Active = 95.7

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 15)

Average Co-Inventor Count = 1.7

ph-index = 7

Forward Citations = 142(Granted Patents)

Location History:

Bronx, NY (US) (2013 - 2022)
New York, NY (US) (2022 - 2024)

Company Filing History:

20 out of 21

Beyondspring Pharmaceuticals, Inc.

Hywe Pharmaceuticals, Inc.

patent

4. 1 out of 1

Yolare Pharmaceuticals, LLC

patent

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Neutropenia

Plinabulin

Cancer Treatment

Checkpoint Inhibitors

Tubulin Binding Compounds

Thrombocytopenia

RAS Mutation

Brain Tumor

Therapeutic Compositions

Combination Therapies

Modified Collagenase

Beta-Elemene

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12458639 - Tubulin binding compounds and therapeutic use thereof (2025-11-04),

2. 12458638 - Method of stimulating neutrophil survival and reducing neutropenia (2025-11-04),

3. 12433886 - Composition and method for reducing neutropenia (2025-10-07),

4. 12377094 - Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies (2025-08-05),

5. 12024501 - Plinabulin compositions (2024-07-02),

6. 11918574 - Method of treating cancer associated with a RAS mutation (2024-03-05),

7. 11857522 - Compositions containing tucaresol or its analogs (2024-01-02),

8. 11786523 - Composition and method for reducing thrombocytopenia (2023-10-17),

9. 11633393 - Tubulin binding compounds and therapeutic use thereof (2023-04-25),

10. 11400086 - Method of reducing chemotherapy-induced neutropenia (2022-08-02),

11. 11254657 - Plinabulin compositions (2022-02-22),

12. 11229642 - Composition and method for reducing neutropenia (2022-01-25),

13. 11045467 - Method of treating cancer associated with a RAS mutation (2021-06-29),

14. 10912748 - Compositions containing tucaresol or its analogs (2021-02-09),

15. 10668063 - Method of treating cancer associated with a RAS mutation (2020-06-02),

Title: Innovator Spotlight: Lan Huang and His Contributions to Cancer Treatment

Introduction: Lan Huang, based in Bronx, NY, is a prominent inventor recognized for his significant contributions to pharmaceutical innovation. With an impressive portfolio of 19 patents, Huang's work primarily focuses on therapeutic agents for cancer treatment. His dedication to advancing medical technology places him among the noteworthy inventors in the field.

Latest Patents: Among Huang's latest patents are groundbreaking advancements in cancer treatment. The first patent, titled "Plinabulin compositions," discloses various plinabulin polymorphs and their preparation for use as therapeutic agents. A key aspect of this patent is the plinabulin monohydrate in crystalline form, which holds promise for enhanced efficacy. The second patent, "Method of treating cancer associated with a RAS mutation," outlines innovative methods for treating cancers that express mutant forms of RAS proteins. This patent emphasizes the application of plinabulin as a treatment for affected individuals, showcasing Huang's commitment to addressing critical healthcare challenges.

Career Highlights: Over the years, Lan Huang has worked with notable companies such as Beyondspring Pharmaceuticals, Inc. and Beyondspring Inc. His contributions to these organizations have been instrumental in developing and advancing new therapeutic options that aim to improve patient outcomes.

Collaborations: Throughout his career, Huang has collaborated with esteemed colleagues, including Ramon Mohanlal and George Kenneth Lloyd. These partnerships have facilitated a dynamic exchange of ideas, further enhancing the innovative spirit of their collective endeavors.

Conclusion: Lan Huang's contributions to the field of cancer treatment through his innovative patents highlight his dedication to improving healthcare. His work not only represents a significant advancement in pharmaceutical sciences but also showcases the importance of collaboration and innovation in the fight against cancer. As we look forward to future advancements, Huang's ongoing research and development efforts serve as a beacon of hope in the medical community.

Profile summary based on public USPTO records.